AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MESOBLAST LTD

2.340

-0.020-0.85%

Volume:1.88M

Turnover:4.34M

Market Cap:3.03B

PE:-37.78

High:2.345

Open:2.320

Low:2.280

Close:2.360

52wk High:3.310

52wk Low:1.880

Shares:1.30B

Float Shares:786.49M

Volume Ratio:0.66

T/O Rate:0.24%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.062

EPS(LYR):-0.062

ROE:-9.86%

ROA:-4.11%

PB:3.83

PE(LYR):-37.78

Loading ...

Overview Company News Filings

Mesoblast Draws $50 Million From Facility Provided by Shareholder

MT Newswires Live

Press Release: Mesoblast Draws US$50 Million from Five-year Non-dilutive Facility

Mesoblast (ASX:MSB) Is Up 9.2% After Ryoncil’s Near-US$100m Debut And Revascor FDA Progress – Has The Bull Case Changed?

Simply Wall St.

Mesoblast Says JPMorgan Ceases to be Substantial Holder

MT Newswires Live

Kina Securities And 2 Other Stocks That May Be Trading Below Their Estimated Value On The ASX

Simply Wall St.

Mesoblast Ltd-ASX CEO Connect Presentation

THOMSON REUTERS

ASX Growth Companies With High Insider Ownership

Simply Wall St.

ASX Penny Stocks With Market Caps Under A$3B To Consider

Simply Wall St.

Assessing Mesoblast (ASX:MSB) Valuation After Phase 3 Recruitment Milestone For Rexlemestrocel L

Simply Wall St.

Is Completing Phase 3 Enrollment For Rexlemestrocel-L Reshaping The Investment Case For Mesoblast (ASX:MSB)?

Simply Wall St.

Mesoblast posts Q3 Ryoncil net revenue of US$30.3 million

Mesoblast Reports Ryoncil® Net Revenues of US$30.3M and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million

THOMSON REUTERS

Stock Track | Mesoblast Plummets 5.41% Intraday Following Quarterly Ryoncil Revenue Report

Mesoblast Ltd - Reports Qtrly Ryoncil Net Revenues of $30.3 Mln

THOMSON REUTERS

ASX Growth Companies With High Insider Ownership In April 2026

Simply Wall St.

Mesoblast files Form 3 as director Lynette Cobley reports beneficial ownership

Stock Track | Mesoblast Soars 5.12% Intraday on Patient Recruitment Milestone in Phase 3 Back Pain Trial

BUZZ-ASX-shares of Mesoblast rise after back-treatment drug hits patent target

Mesoblast hits recruitment target in Phase 3 chronic low back pain trial

Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/MSB.AU/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.34,"timestamp":1788240634797,"preClose":2.36,"halted":0,"volume":1876875,"delay":0,"changeRate":-0.00847457627118645,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1296862776,"eps":-0.06193634784792117,"marketStatus":"Trading","change":-0.02,"latestTime":"09-01 15:31:29 AEST","open":2.32,"high":2.345,"low":2.28,"amount":4342543,"amplitude":0.027542,"askPrice":2.34,"askSize":19079,"bidPrice":2.33,"bidSize":30814,"shortable":3,"etf":0,"ttmEps":-0.06193634784792117,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788242400000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":2.36,"openAndCloseTimeList":[[1788220800000,1788242400000]],"volumeRatio":0.658955,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MSB.AU","preClose":2.36,"auctionPrice":2.32,"auctionVolume":11794,"auctionTime":1788220751317,"referenceTime":1788172203092,"auction":1,"marketStatus":"盘前竞价","timestamp":1788220751317}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-4.11%","roe":"-9.86%","lyrEps":-0.061935,"volumeRatio":0.658955,"shares":1296862776,"dividePrice":0,"high":2.345,"amplitude":0.027542,"preClose":2.36,"low":2.28,"week52Low":1.88,"pbRate":"3.83","psRate":"18.09","week52High":3.31,"institutionHeld":0,"latestPrice":2.34,"committee":0.235203,"eps":-0.061934533524158654,"divideRate":0,"volume":1876875,"delay":0,"ttmEps":-0.061934533524158654,"open":2.32,"prevYearClose":2.72,"prevWeekClose":2.46,"prevMonthClose":2.36,"prevQuarterClose":1.955,"fiveDayClose":2.35,"twentyDayClose":2.08,"sixtyDayClose":2.04,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787702400000,"name":null,"time":"","dateTimestamp":1787666400000,"actualEps":null},{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2646847745","title":"Mesoblast Draws $50 Million From Facility Provided by Shareholder","url":"https://stock-news.laohu8.com/highlight/detail?id=2646847745","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646847745?lang=en_us&edition=fundamental","pubTime":"2026-06-25 09:02","pubTimestamp":1782349359,"startTime":"0","endTime":"0","summary":"Mesoblast  said it drew down $50 million from a five-year facility provided by Gregory George, a shareholder and director of the company, according to a Thursday filing with the Australian bourse.The credit line carries a fixed interest rate of 8% per year, which marks \"a substantial reduction\" from prior facilities, the company said.Mesoblast had $122 million of cash at the end of March and \"is well funded to invest in its commercial operations and growth pipeline,\" it said.The company's shares fell nearly 2% in recent Thursday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MESO","MSB.AU","BK7067","BK7501","BK7508","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646847290","title":"Press Release: Mesoblast Draws US$50 Million from Five-year Non-dilutive Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2646847290","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646847290?lang=en_us&edition=fundamental","pubTime":"2026-06-25 08:59","pubTimestamp":1782349140,"startTime":"0","endTime":"0","summary":"Optimized capital structure, retiring short-term maturing debtWell-funded for commercial operations and growth pipelineNEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:M","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4150","BK4006","BK7067","BK4575","MSC","BK4022","MSB.AU","BK7501","MSB","BK4139","BK4232","BK7508","MESO","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645965180","title":"Mesoblast (ASX:MSB) Is Up 9.2% After Ryoncil’s Near-US$100m Debut And Revascor FDA Progress – Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2645965180","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645965180?lang=en_us&edition=fundamental","pubTime":"2026-06-21 00:29","pubTimestamp":1781972983,"startTime":"0","endTime":"0","summary":"Earlier this week, Mesoblast reported that Ryoncil’s first-year US launch revenue approached about US$100 million, alongside continued FDA engagement on an accelerated-approval pathway and Biologics License Application for heart failure therapy Revascor.\nThis combination of early commercial traction for Ryoncil and active regulatory dialogue on Revascor has sharpened investor focus on Mesoblast’s broader cell therapy pipeline and execution risks.\nWe’ll now examine how Ryoncil’s early US...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-92-after-ryoncils-near-us100m-debut-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-92-after-ryoncils-near-us100m-debut-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","BK4097","BK7067","BK7508","BK4588","BK4585","BK4006","MSB.AU","PRGS","MSB","LABU","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642259232","title":"Mesoblast Says JPMorgan Ceases to be Substantial Holder","url":"https://stock-news.laohu8.com/highlight/detail?id=2642259232","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642259232?lang=en_us&edition=fundamental","pubTime":"2026-06-12 11:38","pubTimestamp":1781235489,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) said JPMorgan Chase and its affiliates ceased to be substantial holders of the firm on Tuesday, according to a Friday Australian bourse filing.Its shares rose 1% in recent trading on Friday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1670627923.USD","LU1974910355.USD","BK4550","LU1894683348.USD","LU1261432733.SGD","LU2357305700.SGD","IE00BLSP4452.SGD","IE00BFXG1179.USD","SG9999002232.USD","JPM","LU0859254822.USD","LU1551013342.USD","LU1670628061.USD","LU2552382215.SGD","BK4139","LU2237443895.HKD","LU1119994496.HKD","MESO","LU0211326755.USD","LU2430703251.USD","LU2213496289.HKD","LU2237443465.HKD","LU2462157665.USD","LU1668664300.SGD","LU0345770993.USD","JPMO","MSB.AU","LU0211331839.USD","LU0048584097.USD","LU2237443549.SGD","IE00BKDWB100.SGD","LU0976567544.SGD","LU1116320737.USD","PGF","LU1162221912.USD","JPX","LU0417517546.SGD","JPO","IE0034235295.USD","LU2023250504.SGD","LU0211326839.USD","IE00BBT3K403.USD","LU0868494708.USD","LU2211815571.USD","LU2430703095.HKD","LU1244550221.USD","LU1914381329.SGD","IE00BDCRKT87.USD","LU0256863902.USD","LU2237443622.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642026239","title":"Kina Securities And 2 Other Stocks That May Be Trading Below Their Estimated Value On The ASX","url":"https://stock-news.laohu8.com/highlight/detail?id=2642026239","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642026239?lang=en_us&edition=fundamental","pubTime":"2026-06-12 03:04","pubTimestamp":1781204699,"startTime":"0","endTime":"0","summary":"In the midst of a challenging period for Australian shares, with market sentiment swayed by geopolitical tensions and economic uncertainties, investors are increasingly on the lookout for opportunities in undervalued stocks. Identifying stocks that may be trading below their estimated value can offer potential upside, especially when broader market volatility prompts a shift towards more defensive investment strategies.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/kina-securities-and-2-other-stocks-that-may-be-trading-below","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/kina-securities-and-2-other-stocks-that-may-be-trading-below","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["FDV.AU","KSL.AU","MSB.AU","BK7055","BK7067","KGN.AU","RDY.AU","LOV.AU","JDO.AU","BK7135","BK7016","NWH.AU","NGI.AU","BK7508","SYL.AU","BK7501","BK7049","BK7062","BK7153","BK7128","MFG.AU","NXL.AU","BK7002"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640996638","title":"Mesoblast Ltd-ASX CEO Connect Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2640996638","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640996638?lang=en_us&edition=fundamental","pubTime":"2026-06-02 09:51","pubTimestamp":1780365084,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUE13GZMZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","BK7067","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640898689","title":"ASX Growth Companies With High Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2640898689","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640898689?lang=en_us&edition=fundamental","pubTime":"2026-06-01 03:08","pubTimestamp":1780254489,"startTime":"0","endTime":"0","summary":"As Australian shares rebound from a significant market downturn, driven by global events and domestic fiscal policies, investors are keenly observing the landscape for opportunities. In this environment, growth companies with high insider ownership can be particularly appealing due to their potential for alignment of interests between management and shareholders.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551736-choice1-main-header/1585186738088","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551736-choice1-main-header/1585186738088"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/diversified-financials/asx-hmc/hmc-capital-shares/news/asx-growth-companies-with-high-insider-ownership-13","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/diversified-financials/asx-hmc/hmc-capital-shares/news/asx-growth-companies-with-high-insider-ownership-13","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IIGF.AU","E200.AU","BBOZ.AU","GEAR.AU","BK7005","BEAR.AU","EIGA.AU","BK7023","VAS.AU","BK7110","SKS.AU","BK7104","SPL.AU","DACE.AU","GIVE.AU","EIQ.AU","AEM.AU","MSB.AU","BK7508","STW.AU","QRE.AU","BK7067","IOZ.AU","BK7017","IMLC.AU","BK7062","OZF.AU","XAO.AU","SLF.AU","TOR.AU","BK7096","BK7095","IISV.AU","VAP.AU","ZYAU.AU","XKO.AU","BK7501","FRS.AU","XJO.AU","OZR.AU","QFN.AU","AR1.AU","PNI.AU","AV1.AU","BK7162","BK7016","MAU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638656561","title":"ASX Penny Stocks With Market Caps Under A$3B To Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=2638656561","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638656561?lang=en_us&edition=fundamental","pubTime":"2026-05-28 10:05","pubTimestamp":1779933920,"startTime":"0","endTime":"0","summary":"Australian shares are poised for a slight retreat, influenced by Wall Street's recent cooling and ongoing global economic discussions. Despite the fluctuating market conditions, penny stocks—often overlooked due to their smaller size or newer status—can still present valuable opportunities when backed by solid financials. In this article, we explore several promising Australian penny stocks that combine financial strength with potential for long-term growth.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-ami/aurelia-metals-shares/news/asx-penny-stocks-with-market-caps-under-a3b-to-consider","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-ami/aurelia-metals-shares/news/asx-penny-stocks-with-market-caps-under-a3b-to-consider","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EIGA.AU","GDG.AU","E200.AU","ZYAU.AU","BK7095","IMLC.AU","BK7508","IIGF.AU","BK7506","GEAR.AU","VAS.AU","IOZ.AU","BK7067","AMI.AU","OZF.AU","QRE.AU","XAO.AU","BK7089","MSB.AU","QFN.AU","BEAR.AU","VAP.AU","BBOZ.AU","GIVE.AU","IISV.AU","XKO.AU","SLF.AU","BK7501","OZR.AU","XJO.AU","STW.AU","DACE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633972051","title":"Assessing Mesoblast (ASX:MSB) Valuation After Phase 3 Recruitment Milestone For Rexlemestrocel L","url":"https://stock-news.laohu8.com/highlight/detail?id=2633972051","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633972051?lang=en_us&edition=fundamental","pubTime":"2026-05-07 11:57","pubTimestamp":1778126267,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) has reached full patient recruitment for its pivotal Phase 3 trial of rexlemestrocel-L in chronic low back pain, a key step toward confirmatory data supporting a potential US regulatory filing.\nSee our latest analysis for Mesoblast.\nDespite the latest clinical milestone, Mesoblast’s 1 day share price return of a 4.13% decline and 7 day share price return of a 5.86% decline show some cooling momentum. However, the 3 year total shareholder return of 102.23% reflects a strong...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblast-asxmsb-valuation-after-phase-3-recruitme","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblast-asxmsb-valuation-after-phase-3-recruitme","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","MSB","MSB.AU","BK7067","BK4006","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632227266","title":"Is Completing Phase 3 Enrollment For Rexlemestrocel-L Reshaping The Investment Case For Mesoblast (ASX:MSB)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2632227266","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632227266?lang=en_us&edition=fundamental","pubTime":"2026-05-02 11:34","pubTimestamp":1777692888,"startTime":"0","endTime":"0","summary":"In late April 2026, Mesoblast Limited reported it had completed patient recruitment for its pivotal 300-patient Phase 3 trial of rexlemestrocel-L in chronic low back pain due to degenerative disc disease, a placebo-controlled study designed around a 12-month pain reduction endpoint and supported by the therapy’s RMAT designation.\nThis milestone moves rexlemestrocel-L closer to potential FDA submission for a condition affecting over 7 million Americans and heavily tied to opioid use,...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-completing-phase-3-enrollment-for-rexlemestrocel-l-reshap","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-completing-phase-3-enrollment-for-rexlemestrocel-l-reshap","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4006","BK7501","BK7067","MSB.AU","MSB","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631601579","title":"Mesoblast posts Q3 Ryoncil net revenue of US$30.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2631601579","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631601579?lang=en_us&edition=fundamental","pubTime":"2026-04-30 08:55","pubTimestamp":1777510520,"startTime":"0","endTime":"0","summary":"Mesoblast reported fiscal third-quarter net revenue from Ryoncil of US$30.3 million on gross sales of US$35.3 million.Net operating cash spend narrowed to US$4.1 million, supported by receipts of US$34.6 million.Cash on hand totaled US$122 million at March 31, 2026.Patient recruitment target was reached in pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain.Exclusive worldwide license was secured for patented CAR technology platform to develop precision-enhanced MSC products.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL6rmgv1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU0314104364.USD","BK7508","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014005.SGD","LU2095319765.USD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","BK7067","BK7501","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4585","BK4588","IE00B3QW5Z07.USD","SG9999014039.USD","MSB.AU","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631796605","title":"Mesoblast Reports Ryoncil® Net Revenues of US$30.3M and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2631796605","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631796605?lang=en_us&edition=fundamental","pubTime":"2026-04-30 08:55","pubTimestamp":1777510501,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUA9R8J7T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4533","BK7067","LU1894683264.USD","MSB.AU","LU1894683348.USD","BK4534","SG9999002224.SGD","LU0683600562.USD","BK7508","BK7501","LU2264538146.SGD","MMM","BK4206","LU1064131342.USD","LU1093756168.USD","LU0787776722.HKD","IE000M9KFDE8.USD","LU1093756325.SGD","BK4512","SG9999002232.USD","LU1988902786.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148152415","title":"Stock Track | Mesoblast Plummets 5.41% Intraday Following Quarterly Ryoncil Revenue Report","url":"https://stock-news.laohu8.com/highlight/detail?id=1148152415","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148152415?lang=en_us&edition=fundamental","pubTime":"2026-04-30 08:30","pubTimestamp":1777509035,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd's stock price dropped sharply by 5.41% during intraday trading on Thursday, as investors reacted to the company's latest quarterly financial update.The decline came shortly after...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631575532","title":"Mesoblast Ltd - Reports Qtrly Ryoncil Net Revenues of $30.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2631575532","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631575532?lang=en_us&edition=fundamental","pubTime":"2026-04-30 07:57","pubTimestamp":1777507051,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nFWN41C20G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","MSB.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631520999","title":"ASX Growth Companies With High Insider Ownership In April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2631520999","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631520999?lang=en_us&edition=fundamental","pubTime":"2026-04-30 03:08","pubTimestamp":1777489699,"startTime":"0","endTime":"0","summary":"As Australian shares enter their seventh consecutive day in the red, market sentiment has shifted into bearish territory amid concerns over rising inflation and potential interest rate hikes. In this challenging environment, growth companies with high insider ownership can be appealing as they often indicate strong confidence from those who know the business best.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2054000-choice2-main-header/1585187245570","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2054000-choice2-main-header/1585187245570"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-ipx/iperionx-shares/news/asx-growth-companies-with-high-insider-ownership-in-april-20-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-ipx/iperionx-shares/news/asx-growth-companies-with-high-insider-ownership-in-april-20-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SKS.AU","TOR.AU","BK7116","AEM.AU","MSB.AU","BK7104","EIQ.AU","BK7023","BK7095","MAU.AU","FRS.AU","BK7084","AR1.AU","BK7096","XAO.AU","BK7508","XJO.AU","XKO.AU","BK7501","BK7094","BK7067","SPL.AU","BK7110","BK7016","ELS.AU","IPX.AU","AV1.AU","BK7017","AYA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631759459","title":"Mesoblast files Form 3 as director Lynette Cobley reports beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2631759459","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631759459?lang=en_us&edition=fundamental","pubTime":"2026-04-29 18:22","pubTimestamp":1777458121,"startTime":"0","endTime":"0","summary":"Mesoblast Form 3 shows director Lynette Elizabeth Cobley reporting 63,000 ordinary shares as of March 18, 2026.Filing also discloses 200,000 options exercisable at $1.72, expiring May 9, 2032.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL66nDbR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7067","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156659915","title":"Stock Track | Mesoblast Soars 5.12% Intraday on Patient Recruitment Milestone in Phase 3 Back Pain Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1156659915","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156659915?lang=en_us&edition=fundamental","pubTime":"2026-04-29 11:50","pubTimestamp":1777434632,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd's stock surged 5.12% during intraday trading on Wednesday, following the company's announcement of a key development milestone for its chronic low back pain treatment.The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631455426","title":"BUZZ-ASX-shares of Mesoblast rise after back-treatment drug hits patent target","url":"https://stock-news.laohu8.com/highlight/detail?id=2631455426","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631455426?lang=en_us&edition=fundamental","pubTime":"2026-04-29 11:22","pubTimestamp":1777432976,"startTime":"0","endTime":"0","summary":"BUZZ-ASX-shares of Mesoblast rise after back-treatment drug hits patent target** Australian shares of Mesoblast MSB.AX rise as much as 4.2% to A$2.24, their biggest intraday pct gain since April 22** Stock among the top gainers in Australia's S&P/ASX 200 index .AXJO, which is down 0.3%** Stock set for a second consecutive session of gains, if current trend holds** The drugmaker says its lower back-treating drug, rexlemestrocel-L, has achieved patient recruitment target** The patent protects the drug from competition, supports higher longterm revenues** Despite moves, MSB down 17.8% YTD  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nL6N41C048:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB.AU","BK7501","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631553071","title":"Mesoblast hits recruitment target in Phase 3 chronic low back pain trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2631553071","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631553071?lang=en_us&edition=fundamental","pubTime":"2026-04-29 08:53","pubTimestamp":1777424014,"startTime":"0","endTime":"0","summary":"Mesoblast hit recruitment target in pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain tied to degenerative disc disease.Top-line results have not been presented yet; readout is expected in mid-CY2027.Study is designed to confirm earlier findings that rexlemestrocel-L reduced pain and supported lower opioid use.Positive results are intended to support an FDA filing in Q3 CY2027, with RMAT status positioning program for priority review once BLA is filed.Mesoblast framed indication as major commercial opportunity, citing potential peak-year revenue above USD 10 billion with single-digit market penetration.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL6PvWb7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","BK4585","SG9999014039.USD","BK7067","SG9999014005.SGD","LU2095319765.USD","BK4588","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","NDAQ","LU2210150020.SGD","MSB.AU","BK7501","LU2210149790.SGD","LU0314104364.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631553020","title":"Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2631553020","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631553020?lang=en_us&edition=fundamental","pubTime":"2026-04-29 08:53","pubTimestamp":1777423996,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUABQ0Y0N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","MSB.AU","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":187,"code":"91000000","status":"200"}]}}